Short facts  
API BI1029539
Technology Oral
Indication Microvascular disease
Development phase Fas 1
Expected filing with FDA -
In-house or partnership Partnership with Gesynta Pharma AB

The concept

Cardiovascular morbidity and mortality are common in chronic inflammatory diseases due to vascular inflammation and endothelial dysfunction. The lead candidate drug, BI1029539, has been identified as a highly selective anti-inflammatory compound targeting microsomal prostaglandin E synthase (mPGES-1). 

Selective deletion of mPGES-1 activity leads to anti- inflammatory, vasodilatory and platelet inhibitory effects.

The project is developed by Orexo´s partner Gesynta Pharma AB who owns all the rights to the project.